Literature DB >> 565059

Processes regulating the functional activity of brain 5-hydroxytryptamine: results of animal experimentation and their relevance to the understanding and treatment of depression.

A R Green, D G Grahame-Smith.   

Abstract

Investigation has been made into the processes regulating the function activity of rat brain 5-hydroxytryptamine (5-HT) and the way that drugs used to treat depression act on these processes. Use was made of both biochemical measurements and a behavioural model in which the hyperactivity which follows increased 5-HT synthesis and release was measured as an index of functional activity of the amine. The following mechanisms are suggested to be important in the control of 5-HT function. Presynaptic mechanisms; precursor availability and the transport of tryptophan across the neuronal membrane, intraneuronal metabolism by monoamine oxidase, compartmentation, release and re-uptake. Postsynaptic mechanisms; the sensitivity of the post-synaptic receptor, the role of peptides in altering the size of the post-synaptic response and the action of other neurotransmitters controlling the magnitude of the postsynaptic response. In this regard 5-HT function has been shown to be altered by both dopamine and GABA. The action of anti-depressant drugs on these mechanisms is discussed.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 565059     DOI: 10.1055/s-0028-1094558

Source DB:  PubMed          Journal:  Pharmakopsychiatr Neuropsychopharmakol        ISSN: 0031-7098


  4 in total

1.  David Grahame Grahame-Smith: clinical pharmacologist. 1933-2011.

Authors:  Jeffrey K Aronson
Journal:  Br J Clin Pharmacol       Date:  2012-05       Impact factor: 4.335

2.  The activities of monoamine oxidase-A and -B, succinate dehydrogenase and acid phosphatase in the rat brain after hemitransection.

Authors:  A Carlsson; C J Fowler; T Magnusson; L Oreland; A Wiberg
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1981-02       Impact factor: 3.000

Review 3.  Clinical pharmacokinetics of the monoamine oxidase-A inhibitor moclobemide.

Authors:  M Mayersohn; T W Guentert
Journal:  Clin Pharmacokinet       Date:  1995-11       Impact factor: 6.447

4.  Monoamine oxidase-A and -B activities in the brain stem of schizophrenics and non-schizophrenic psychotics.

Authors:  C J Fowler; A Carlsson; B Winblad
Journal:  J Neural Transm       Date:  1981       Impact factor: 3.575

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.